Ozanimod for treating relapsing-remitting multiple sclerosis has now been rescheduled into the work programme and is due to be discussed at committee on 10 December 2020. The topic webpage will be updated with the new timelines and expected publication date in due course.
The new timelines are subject to staff capacity and the ongoing management of the COVID-19 situation and we will continue to review our plans and update our stakeholders accordingly.